We demonstrate that miR-7 therapy leads to repression of multiple genes involved in the pathogenesis of ACC, including Raf-1 proto-oncogene serine/threonine kinase (RAF1), mechanistic target of rapamycin (MTOR) and cyclin dependent kinase 1 (CDK1). The gene discussed is MTOR; the disease is adrenal cortex carcinoma.